The Food and Drug Administration could expand the use of Pfizer-BioNTech’s Covid-19 vaccine to children ages 6 months to 5 years by the end of February, a person with knowledge of the plan said.
Federal regulators want to begin reviewing the data on two doses of the vaccine for this age group while the companies continue to gather data on a potential three-dose regimen, the person said.
The FDA is expected to eventually sign off on three doses for kids under 5, but regulators believe two doses in the meantime should provide enough — though less than ideal — protection against the omicron variant, the individual said.
Omicron accounts for virtually all new Covid cases in the United States, according to the Centers for Disease Control and Prevention. The new variant has led to a dramatic spike in pediatric cases.
Children under 5 are the only group in the U.S. not authorized to receive a Covid vaccine. Pfizer’s vaccine has been cleared for kids as young as 5, while Moderna and Johnson & Johnson’s vaccines are authorized for adults.
Pfizer has not yet filed a submission to the FDA to authorize its vaccine for kids under 5, the company said in a statement Monday. “We’re continuing to collect and analyze data from both two and three doses in our younger age cohort,” the company said.
However, the person familiar with the plans says the submission is expected this week, possibly as early as Tuesday.
There are an estimated 19.5 million children under 5 in the U.S. and Puerto Rico.